These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 14566675)

  • 1. The role of chromosome 8p22 deletion for predicting disease progression and pathological staging in prostate cancer.
    Matsuyama H; Pan Y; Oba K; Yoshihiro S; Matsuda K; Hägarth L; Kudren D; Naito K; Bergerheim US; Ekman P
    Aktuelle Urol; 2003 Jul; 34(4):247-9. PubMed ID: 14566675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer.
    Matsuyama H; Pan Y; Oba K; Yoshihiro S; Matsuda K; Hägarth L; Kudren D; Naito K; Bergerheim US; Ekman P
    Clin Cancer Res; 2001 Oct; 7(10):3139-43. PubMed ID: 11595707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer.
    Matsuyama H; Pan Y; Yoshihiro S; Kudren D; Naito K; Bergerheim US; Ekman P
    Prostate; 2003 Feb; 54(2):103-11. PubMed ID: 12497583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
    Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
    Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization.
    Matsuyama H; Pan Y; Skoog L; Tribukait B; Naito K; Ekman P; Lichter P; Bergerheim US
    Oncogene; 1994 Oct; 9(10):3071-6. PubMed ID: 8084616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer.
    Jenkins R; Takahashi S; DeLacey K; Bergstralh E; Lieber M
    Genes Chromosomes Cancer; 1998 Feb; 21(2):131-43. PubMed ID: 9491325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haploinsufficiency of 8p22 may influence cancer-specific survival in prostate cancer.
    Matsuyama H; Oba K; Matsuda K; Yoshihiro S; Tsukamoto M; Kinjo M; Sagiyama K; Takei M; Yamaguchi A; Sasaki K; Naito K
    Cancer Genet Cytogenet; 2007 Apr; 174(1):24-34. PubMed ID: 17350463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer.
    Macoska JA; Trybus TM; Sakr WA; Wolf MC; Benson PD; Powell IJ; Pontes JE
    Cancer Res; 1994 Jul; 54(14):3824-30. PubMed ID: 8033102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas.
    Utada Y; Haga S; Kajiwara T; Kasumi F; Sakamoto G; Nakamura Y; Emi M
    Cancer; 2000 Mar; 88(6):1410-6. PubMed ID: 10717624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma.
    Takahashi S; Alcaraz A; Brown JA; Borell TJ; Herath JF; Bergstralh EJ; Lieber MM; Jenkins RB
    Clin Cancer Res; 1996 Jan; 2(1):137-45. PubMed ID: 9816100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular biological analysis of the heterogeneous prostate cancer group Gleason score 7.
    Mian C; Lodde M; Comploj E; Palermo S; Lusuardi L; Marziani F; Chiocchetti A; Spada A; Mian M; Pycha A
    Prostate; 2006 Jun; 66(9):966-70. PubMed ID: 16541423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer.
    Fromont G; Valeri A; Cher M; Pontes JE; Vallancien G; Validire P; Latil A; Cussenot O
    Prostate; 2005 Dec; 65(4):341-6. PubMed ID: 16015610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy.
    Valeri A; Fromont G; Sakr W; Azzouzi R; Dey J; Chantrel-Groussard K; Latil A; Berthon P; Cussenot O; Pontes JE; Cher ML
    Urol Oncol; 2005; 23(2):87-92. PubMed ID: 15869992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic profile identification in clinically localized prostate carcinoma.
    Gallucci M; Merola R; Leonardo C; De Carli P; Farsetti A; Sentinelli S; Sperduti I; Mottolese M; Carlini P; Vico E; Simone G; Cianciulli A
    Urol Oncol; 2009; 27(5):502-8. PubMed ID: 18534873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
    Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
    Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer.
    Huang SF; Xiao S; Renshaw AA; Loughlin KR; Hudson TJ; Fletcher JA
    Am J Pathol; 1996 Nov; 149(5):1565-73. PubMed ID: 8909246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
    Swindle P; Eastham JA; Ohori M; Kattan MW; Wheeler T; Maru N; Slawin K; Scardino PT
    J Urol; 2005 Sep; 174(3):903-7. PubMed ID: 16093984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
    Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
    Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.